Dr Katie Wynne
Conjoint Associate Professor
School of Medicine and Public Health
- Email:katie-jane.wynne@newcastle.edu.au
- Phone:02 4921 4380
Career Summary
Biography
I am a Clinical Endocrinologist with a conjoint appointment with University of Newcastle. I graduated with a degree in Medical Science and Experimental Psychology from Cambridge University in 1996. I completed my MBBS medical degree at King’s College London in 1999 and then joined Imperial College London as a Wellcome Trust Clinical Research Fellow, completing a PhD in 2007. My postdoctoral research was in the field of appetite control as a National Institute for Health Research Clinical Lecturer. I moved to Newcastle, Australia in 2012 and continue to research and publish in the field of endocrinology, with special interest in transgender medicine, antenatal endocrinology and metabolic health.
Keywords
- antenatal endocrinology
- diabetes
- metabolic disease
- obesity
- transgender health science
Professional Experience
Academic appointment
Dates | Title | Organisation / Department | ||
---|---|---|---|---|
1/8/2019 - | Senior Staff Specialist and Conjoint Associate Professor | Discipline of Human Physiology, School of Biomedical Sciences and Pharmacy, Faculty of health and Medicine, University of Newcastle Australia |
||
1/11/2018 - 31/7/2019 |
Senior Staff Specialist and Conjoint Senior Lecturer Senior Staff Specialist and Conjoint Senior Lecturer Endocrinology & Diabetes, John Hunter Hospital, NSW. |
Discipline of Human Physiology, School of Biomedical Sciences and Pharmacy, Faculty of health and Medicine, University of Newcastle Australia |
||
1/9/2010 - 1/11/2012 |
Senior Lecturer
|
Imperial College London United Kingdom |
||
1/9/2006 - 1/9/2010 |
National Institute for Health Research Clinical Lecturer
|
Imperial College London United Kingdom |
||
1/9/2003 - 1/9/2006 |
Wellcome Trust Clinical Research Fellow
|
Imperial College London United Kingdom |
Awards
Award
Year | Award |
---|---|
2022 |
Equity, Diversity and Inclusion Award: Queer Med Ed Project College Health, Medicine and Wellbeing - The University of Newcastle (Australia) |
2022 |
ACI HNE Rural Innovation Award NSW Agency for Clinical Innovation (ACI) |
Nomination
Year | Award |
---|---|
2022 |
Excellence Award: Supportive Care, what matters most? Hunter New England Area Health Service |
2018 |
Excellence Awards: Sweet Dreams: Managing Severe Complex Obesity Hunter New England Area Health Service |
2018 |
Excellence Awards: Better Outcomes for Women with Gestational Diabetes Hunter New England Area Health Service |
2017 |
Excellence Awards: A Pathway to Transgender Health: a community model of care Hunter New England Area Health Service |
Prize
Year | Award |
---|---|
2022 |
Australian Council on Healthcare Standards Quality Initiative Award in Clinical Excellence and Patient Safety. Australian Council on Healthcare Standards (ACHS) |
2022 |
Faculty Opinions Member of the Year: 2020 Faculty Member of the Year Award for Obstetrics, Gynecology & Women’s Health Faculty Opinions |
2006 |
Britain’s Top Younger Bioscience Researchers Award Scientists Engineers and Technologists for Britain |
2006 |
Britain’s Top Younger Bioscience Researchers Award Scientists Engineers and Technologists for Britain |
2005 |
Endocrine Society Travel Grant Award for Exceptional Research Endocrine Society |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Book (1 outputs)
Year | Citation | Altmetrics | Link | ||
---|---|---|---|---|---|
2019 |
Heath R, Wynne K, A Guide to Transgender Health State-Of-the-Art Information for Gender-Affirming People and Their Supporters, Praeger, Santa Barbara, California, 268 (2019) [A1]
|
Nova |
Chapter (4 outputs)
Year | Citation | Altmetrics | Link | |||||
---|---|---|---|---|---|---|---|---|
2021 |
Wynne K, Dornhorst A, 'Diabetes of the Exocrine Pancreas', The Handbook of Clinical Pancreatology, Ergo Advertising Pty Ltd, 2021, Online (2021)
|
|||||||
2015 |
Wynne K, 'Clinical Management of Diabetes in Pregnancy', Advanced Nutrition and Dietetics in Diabetes, John Wiley & Sons, UK 168-175 (2015)
|
|||||||
2011 |
Wynne K, 'VIPomas', Oxford Textbook of Endocrinology and Diabetes, Oxford University Press, UK (2011)
|
|||||||
Show 1 more chapter |
Journal article (60 outputs)
Year | Citation | Altmetrics | Link | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2024 |
Opio J, Wynne K, Attia J, Oldmeadow C, Hancock S, Kelly B, et al., 'Metabolic Health, Overweight or Obesity, and Depressive Symptoms among Older Australian Adults', Nutrients, 16 928-928
|
||||||||||
2024 |
Rowe CW, Rosee P, Sathiakumar A, Ramesh S, Qiao V, Huynh J, et al., 'Factors associated with maternal hyperglycaemia and neonatal hypoglycaemia after antenatal betamethasone administration in women with diabetes in pregnancy.', Diabet Med, 41 e15262 (2024) [C1]
|
Nova | |||||||||
2023 |
Croker EE, Jenkinson C, Ruddell R, Wynne K, 'Severe Hypercalcemia in Pregnancy Presenting a Diagnostic Conundrum.', J Appl Lab Med, 8 984-989 (2023) [C1]
|
Nova | |||||||||
2023 |
Mesure J, Afrin S, Fitzgerald S, Luu J, Gibberd A, Leigh L, Wynne K, 'Oestradiol implants for gender-affirming hormone therapy: an observational study of serum oestradiol levels and consumer survey', Sexual Health, 20 550-557 [C1]
|
Nova | |||||||||
2023 |
Diez Alvarez S, Fellas A, Santos D, Sculley D, Wynne K, Acharya S, et al., 'The Clinical Impact of Flash Glucose Monitoring a Digital Health App and Smartwatch Technology in Patients With Type 2 Diabetes: Scoping Review', JMIR Diabetes, 8 e42389-e42389 [C1]
|
Nova | |||||||||
2023 |
Opio J, Wynne K, Attia J, Hancock S, Oldmeadow C, Kelly B, et al., 'Overweight or obesity increases the risk of cardiovascular disease among older Australian adults, even in the absence of cardiometabolic risk factors: a Bayesian survival analysis from the Hunter Community Study.', Int J Obes (Lond), 47 117-125 (2023) [C1]
|
Nova | |||||||||
2023 |
Rowe CW, Qiao V, Ramesh S, Rosee P, Sathiakumar A, McWhae-Brown S, et al., 'Adoption of a pregnancy-specific intravenous insulin protocol (Pregnancy-IVI) at a regional centre has equivalent safety and efficacy outcomes as a tertiary hospital', Diabetic Medicine, 40 (2023) [C1]
|
Nova | |||||||||
2022 |
Payne E, Palmer G, Rollo M, Ryan K, Harrison S, Collins C, et al., 'Rural healthcare delivery and maternal and infant outcomes for diabetes in pregnancy: A systematic review', NUTRITION & DIETETICS, 79 48-58 (2022) [C1]
|
Nova | |||||||||
2022 |
Taylor R, Rollo ME, Baldwin JN, Hutchesson M, Aguiar EJ, Wynne K, et al., 'Evaluation of a Type 2 diabetes risk reduction online program for women with recent gestational diabetes: a randomised trial', INTERNATIONAL JOURNAL OF BEHAVIORAL NUTRITION AND PHYSICAL ACTIVITY, 19 (2022) [C1]
|
Nova | |||||||||
2022 |
Woodward S, Luu J, Mesure J, Wynne K, 'A collaborative model aligning adult sexual health and endocrine gender health services', SEXUAL HEALTH, 19 386-390 (2022) [C1]
|
Nova | |||||||||
2022 |
Thota RN, Wynne K, Pradeepan S, Wark PAB, Garg ML, 'Association of Islet Amyloid Polypeptide to C-Peptide Ratio with Cystic Fibrosis-Related Diabetes: A Prospective Cross-sectional Study', Pancreas, 51 1029-1036 (2022) [C1] Objectives Early detection of cystic fibrosis (CF) related diabetes (CFRD) improves health outcomes and reduces CF-related mortality. The study aims to evaluate the ratio of islet... [more] Objectives Early detection of cystic fibrosis (CF) related diabetes (CFRD) improves health outcomes and reduces CF-related mortality. The study aims to evaluate the ratio of islet amyloid polypeptide (IAPP) to C-peptide in CF patients with diabetes and without diabetes. Methods Cross-sectional analysis was carried out in a prospective cohort of 33 participants (CF [n=16] and CFRD [n=18]). We examined the association of plasma IAPP:C-peptide ratio with clinical information, including glycated hemoglobin, and lung function markers. Results The median (interquartile range) IAPP:C-peptide ratio was significantly (P=0.004) higher in people with CFRD (4.8 [4.5]) compared with participants without CFRD (12.1 [19.7]). The ratio of IAPP to C-peptide significantly accounted for a 38% variation in the diabetes status in patients with CF (r2=0.399, P < 0.001). Islet amyloid polypeptide is strongly correlated with serum ferritin levels (r=0.683, P=0.005) and forced expiratory volume in CFRD, but not in nondiabetic participants with CF. Conclusions Islet amyloid polypeptide:C-peptide ratio could be a potential marker of CFRD in adults with CF. Further research requires validation of this marker in longitudinal cohort studies to confirm the capability of IAPP:C-peptide to predict CFRD.
|
Nova | |||||||||
2021 |
Rowe CW, Watkins B, Brown K, Delbridge M, Addley J, Woods A, Wynne K, 'Efficacy and safety of the pregnancy-IVI, an intravenous insulin protocol for pregnancy, following antenatal betamethasone in type 1 and type 2 diabetes', Diabetic Medicine, 38 (2021) [C1] Aims: Hyperglycaemia following antenatal corticosteroids is common in women with diabetes in pregnancy, and validated algorithms to maintain pregnancy-specific glucose targets are... [more] Aims: Hyperglycaemia following antenatal corticosteroids is common in women with diabetes in pregnancy, and validated algorithms to maintain pregnancy-specific glucose targets are lacking. The Pregnancy-IVI, an intravenous-insulin (IVI) algorithm, has been validated in gestational diabetes; however, its performance in pre-existing diabetes (Type 1 and Type 2 diabetes) is not known. We hypothesised that Pregnancy-IVI would be superior to a generic Adult-IVI protocol (prior standard of care) following betamethasone in women with pre-existing diabetes. Methods: A retrospective cohort study enrolled all women with pre-existing diabetes at a tertiary centre receiving betamethasone and treated with IVI according to one of two protocols: Adult-IVI (n¿=¿73, 2014¿2017) or Pregnancy-IVI (n¿=¿62, 2017¿2020). The primary outcome was on-IVI glycaemic time-in-range (capillary blood glucose (BGL) 3.8¿7.0¿mmol/L). Secondary outcomes included time with critical hyperglycaemia (BGL¿>¿10¿mmol/L); occurrence of maternal hypoglycaemia (BGL¿<¿3.8¿mmol/l) and incidence of neonatal hypoglycaemia (BGL¿=¿2.5¿mmol/L). Analysis was stratified by diabetes type. Results: Overall, Pregnancy-IVI achieved a higher proportion of on-IVI time-in-range (70%, IQR 56¿78%) compared to Adult-IVI (52%, IQR 41¿69%, p¿<¿0.0001). The duration of critical hyperglycaemia with Pregnancy-IVI was also reduced (2% [IQR 0¿7] vs 8% [IQR 4¿17], p¿<¿0.0001), without an increase in hypoglycaemia. Glycaemic variability was significantly reduced with Pregnancy-IVI. No difference in the rate of neonatal hypoglycaemia was observed. The Pregnancy-IVI was most effective in women with Type 1 diabetes. Conclusion: The Pregnancy-IVI algorithm is safe and effective when used following betamethasone in type 1 diabetes in pregnancy. Further study of women with type 2 diabetes is required.
|
Nova | |||||||||
2021 |
O'Brien JA, McGuire HM, Shinko D, Fazekas de St Groth B, Russo MA, Bailey D, et al., 'T lymphocyte and monocyte subsets are dysregulated in type 1 diabetes patients with peripheral neuropathic pain', Brain, Behavior, and Immunity - Health, 15 (2021) [C1] Diabetic neuropathic pain is a common and devastating complication of type 1 diabetes, but the mechanism by which it develops and persists is yet to be fully elucidated. This stud... [more] Diabetic neuropathic pain is a common and devastating complication of type 1 diabetes, but the mechanism by which it develops and persists is yet to be fully elucidated. This study utilised high-dimensional suspension mass cytometry in a pilot cohort to investigate differences in peripheral blood immunophenotypes between type 1 diabetes patients with (n ¿= ¿9) and without (n ¿= ¿9) peripheral neuropathic pain. The abundance and activation of several leukocyte subsets were investigated with unsupervised clustering approaches FlowSOM and SPADE, as well as by manual gating. Major findings included a proportional increase in CD4+ central memory T cells and an absolute increase in classical monocytes, non-classical monocytes, and mature natural killer cells in type 1 diabetes patients with pain compared to those without pain. The expression of CD27, CD127, and CD39 was upregulated on select T cell populations, and the phosphorylated form of pro-inflammatory transcription factor MK2 was upregulated across most populations. These results provide evidence that distinct immunological signatures are associated with painful neuropathy in type 1 diabetes patients. Further research may link these changes to mechanisms by which pain in type 1 diabetes is initiated and maintained, paving the way for much needed targeted treatments.
|
Nova | |||||||||
2021 |
Kuehn J, Gebuehr A, Wintour J, Woods A, Luu J, Wynne K, 'Significance of hyperglycaemia in first trimester pregnancy (SHIFT): A pilot study and literature review', AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 61 142-146 (2021) [C1]
|
Nova | |||||||||
2021 |
Kannan T, Foster Y, Ho DJ, Gelzinnis SJ, Merakis M, Wynne K, et al., 'Post-Operative Permanent Hypoparathyroidism and Preoperative Vitamin D Prophylaxis', JOURNAL OF CLINICAL MEDICINE, 10 (2021) [C1]
|
Nova | |||||||||
2020 |
Arora M, Walker K, Luu J, Duvivier RJ, Dune T, Wynne K, 'Education of the medical profession to facilitate delivery of transgender health care in an Australian health district', Australian Journal of Primary Health, 26 17-23 (2020) [C1] Transgender individuals who desire medical transition need to access care through their local healthcare system. This is the first study to explore the perceptions of the communit... [more] Transgender individuals who desire medical transition need to access care through their local healthcare system. This is the first study to explore the perceptions of the community and attitudes of healthcare providers towards the delivery of transgender health care in an Australian context. An anonymous survey was conducted of trans and gender-diverse community members; and physicians and trainees in the Hunter New England Local Health District of New South Wales, Australia. Community members were surveyed about their healthcare experiences. Medical students, GPs and hospital physicians were surveyed on their attitudes towards the delivery of transgender health care before and after a 1-h education session that included the lived experience of a community member. Community members expressed a need for increased education for healthcare providers in transgender medicine. Following the intervention, significantly more healthcare providers felt confident to facilitate transgender health care for adults, adolescents and children; and more healthcare providers agreed that medical and surgical treatment should be offered to transgender patients if desired. The positive safety profile of treatment was felt to be the most persuasive factor for the provision of care. Healthcare providers identified a need for health education in transgender medicine; easy access to evidence-based resources; and local referral pathways as key strategies to improving transgender health care.
|
Nova | |||||||||
2020 |
Rollo ME, Baldwin JN, Hutchesson M, Aguiar EJ, Wynne K, Young A, et al., 'The feasibility and preliminary efficacy of an ehealth lifestyle program in women with recent gestational diabetes mellitus: A pilot study', International Journal of Environmental Research and Public Health, 17 1-24 (2020) [C1]
|
Nova | |||||||||
2020 |
Wynne K, Rowe C, Delbridge M, Watkins B, Brown K, Addley J, et al., 'Antenatal corticosteroid administration for foetal lung maturation', F1000Research, 9 1-12 (2020) [C1]
|
Nova | |||||||||
2020 |
Panth N, Dias CB, Wynne K, Singh H, Garg ML, 'Medium-chain fatty acids lower postprandial lipemia: A randomized crossover trial', Clinical Nutrition, 39 90-96 (2020) [C1] Epidemiological and interventional studies have linked saturated fatty acids (SFA) with elevated levels of low-density lipoprotein cholesterol (LDL-C) and increased CVD risk. Howe... [more] Epidemiological and interventional studies have linked saturated fatty acids (SFA) with elevated levels of low-density lipoprotein cholesterol (LDL-C) and increased CVD risk. However, the effects of the SFA chain length on postprandial lipemia in humans are not well elucidated. The aim of this study was to investigate the impact of short, medium and long-chain SFA on postprandial blood lipids in healthy volunteers. Sixteen healthy volunteers consumed test biscuits containing 40 g of either butter (BB), coconut oil (CB) or lard (LB) in a single-blinded, randomized crossover design. Blood samples were collected fasting and 2, 3, 4, and 6 hours postprandially and assessed for blood lipids (total cholesterol, TC; high-density lipoprotein cholesterol, HDL-C; LDL-C and triglyceride, TG). The postprandial TG response following CB was 59.8% lower than following BB (p < 0.01) and 58.8% lower than LB (p < 0.01), although no difference was observed between the BB and the LB responses. The net area under the LDL-C concentration curve was significantly larger after consumption of the CB compared to the BB, despite no significant differences in postprandial net area under the TC and HDL-C concentration curves. Consumption of medium-chain SFA as CB resulted in lower postprandial TG excursions compared to short-chain SFA as BB and long-chain SFA as LB, despite their identical fat and caloric content. These results suggest that SFA differ in their potential to elevate postprandial lipid levels, and that coconut oil, a rich source of medium-chain SFA may not be as hyperlipidemic as animal fats rich in long chain SFA. Anzctr identifier: 12617000903381. Clinical trial registry number: The study was registered with the Australia New Zealand Trial registry as ACTRN12617000903381.
|
Nova | |||||||||
2020 |
Opio J, Croker E, Odongo GS, Attia J, Wynne K, McEvoy M, 'Metabolically healthy overweight/obesity are associated with increased risk of cardiovascular disease in adults, even in the absence of metabolic risk factors: A systematic review and meta-analysis of prospective cohort studies', OBESITY REVIEWS, 21 (2020) [C1]
|
Nova | |||||||||
2020 |
Staats Pires A, Heng B, Tan VX, Latini A, Russo MA, Santarelli DM, et al., 'Kynurenine, Tetrahydrobiopterin, and Cytokine Inflammatory Biomarkers in Individuals Affected by Diabetic Neuropathic Pain', FRONTIERS IN NEUROSCIENCE, 14 (2020) [C1]
|
Nova | |||||||||
2020 |
Tan HLE, McDonald G, Payne A, Yu W, Ismadi Z, Tran H, et al., 'Incidence and Management of Hypertriglyceridemia-Associated Acute Pancreatitis: A Prospective Case Series in a Single Australian Tertiary Centre', JOURNAL OF CLINICAL MEDICINE, 9 (2020) [C1]
|
Nova | |||||||||
2019 |
Rowe CW, Arthurs S, O Neill CJ, Hawthorne J, Carroll R, Wynne K, Bendinelli C, 'High-dose preoperative cholecalciferol to prevent post-thyroidectomy hypocalcaemia: A randomized, double-blinded placebo-controlled trial', Clinical Endocrinology, 90 343-350 (2019) [C1] Objective: Post-thyroidectomy hypocalcaemia is a significant cause of morbidity and prolonged hospitalization, usually due to transient parathyroid gland damage, treated with calc... [more] Objective: Post-thyroidectomy hypocalcaemia is a significant cause of morbidity and prolonged hospitalization, usually due to transient parathyroid gland damage, treated with calcium and vitamin D supplementation. We present a randomized, double-blinded placebo-controlled trial of preoperative loading with high-dose cholecalciferol (300¿000 IU) to reduce post-thyroidectomy hypocalcaemia. Patients and Measurements: Patients (n¿=¿160) presenting for thyroidectomy at tertiary hospitals were randomized 1:1 to cholecalciferol (300¿000¿IU) or placebo 7¿days prior to thyroidectomy. Ten patients withdrew prior to surgery. The primary outcome was post-operative hypocalcaemia (corrected calcium <2.1¿mmol/L in first 180¿days). Results: The study included 150 patients undergoing thyroidectomy for Graves¿ disease (31%), malignancy (20%) and goitre (49%). Mean pre-enrolment vitamin D was 72¿±¿26¿nmol/L. Postoperative hypocalcaemia occurred in 21/72 (29%) assigned to cholecalciferol and 30/78 (38%) participants assigned to placebo (P¿=¿0.23). There were no differences in secondary end-points between groups. In pre-specified stratification, baseline vitamin D status did not predict hypocalcaemia, although most individuals were vitamin D replete at baseline. Post-hoc stratification by day 1 parathyroid hormone (PTH) (<10¿pg/mL, low vs =10¿pg/mL, normal) was explored due to highly divergent rates of hypocalcaemia in these groups. Using a Cox regression model, the hazard ratio for hypocalcaemia in the cholecalciferol group was 0.56 (95%CI 0.32-0.98, P¿=¿0.04) after stratification for Day 1 PTH. Further clinical benefits were observed in these subgroups. Conclusions: Pre-thyroidectomy treatment with high-dose cholecalciferol did not reduce the overall rate of hypocalcaemia following thyroidectomy. In subgroups stratified by day 1 PTH status, improved clinical outcomes were noted.
|
Nova | |||||||||
2019 |
Wynne K, Devereaux B, Dornhorst A, 'Diabetes of the exocrine pancreas', Journal of Gastroenterology and Hepatology (Australia), 34 346-354 (2019) [C1] Diabetes of the exocrine pancreas (DEP) is a form of diabetes that occurs due to pancreatic disease. It is far more common than has been previously considered, with a recent study... [more] Diabetes of the exocrine pancreas (DEP) is a form of diabetes that occurs due to pancreatic disease. It is far more common than has been previously considered, with a recent study showing 1.8% of adults with new-onset diabetes should have been classified as DEP. The majority is misdiagnosed as type 2 diabetes mellitus (T2DM). Patients with DEP exhibit varying degrees of exocrine and endocrine dysfunction. Damage to the islet of Langerhans effects the secretion of hormones from the ß, a, and pancreatic polypeptide cells; the combination of low insulin, glucagon, and pancreatic polypeptide contributes to rapid fluctuations in glucose levels. This form of ¿brittle diabetes¿ may result in the poorer glycemic control observed in patients with DEP, when compared with those with T2DM. Diabetes of the exocrine pancreas has a different natural history to other forms of diabetes; patients are more likely to require early insulin initiation compared with those with T2DM. Therefore, individuals with DEP should be advised about the symptoms of decompensated hyperglycemia, although they are less likely to develop ketoacidosis. Clinicians should screen for DEP in patients with acute or chronic pancreatitis, following pancreatic resection, or with co-existing cystic fibrosis or hemochromatosis. Incident diabetes may herald the onset of pancreatic ductal carcinoma in a small subset of patients. Once identified, patients with DEP can benefit from specific lifestyle advice, pancreatic enzyme replacement therapy, metformin treatment, appropriate insulin dosing, and monitoring. Further research is needed to establish the ideal treatment regimens to provide optimal clinical outcomes for this unique form of diabetes.
|
Nova | |||||||||
2019 |
Rowe CW, Faulkner S, Paul JW, Tolosa JM, Gedye C, Bendinelli C, et al., 'The precursor for nerve growth factor (proNGF) is not a serum or biopsy-rinse biomarker for thyroid cancer diagnosis.', BMC endocrine disorders, 19 128 (2019) [C1]
|
Nova | |||||||||
2019 |
Rowe CW, Putt E, Brentnall O, Gebuehr A, Allabyrne J, Woods A, Wynne K, 'An intravenous insulin protocol designed for pregnancy reduces neonatal hypoglycaemia following betamethasone administration in women with gestational diabetes', Diabetic Medicine, 36 228-236 (2019) [C1] Aims: Marked hyperglycaemia is common following betamethasone administration in women with gestational diabetes (GDM), and may contribute to neonatal hypoglycaemia. Validated prot... [more] Aims: Marked hyperglycaemia is common following betamethasone administration in women with gestational diabetes (GDM), and may contribute to neonatal hypoglycaemia. Validated protocols to deliver glycaemic stability following betamethasone are lacking. We hypothesized that an intravenous insulin (IVI) protocol for pregnancy-specific glycaemic targets (Pregnancy-IVI) would achieve greater at-target glycaemic control than a generic adult intravenous insulin protocol (Adult-IVI), and may reduce neonatal hypoglycaemia. Methods: A retrospective cohort study of the performance Adult-IVI and Pregnancy-IVI following betamethasone in GDM, sequentially implemented at a tertiary hospital, without change in indication for IVI. Cases were identified by electronic record search. Primary outcome was percentage of on-IVI time with at-target glycaemia [blood glucose level (BGL) 3.8¿7¿mmol/l]. Secondary outcomes were time with critical hyperglycaemia (BGL >¿10¿mmol/l), occurrence of maternal hypoglycaemia (BGL <¿3.8¿mmol/l), and incidence of neonatal hypoglycaemia (BGL =¿2.5¿mmol/l) if betamethasone was administered within 48¿h of birth. Results: The cohorts comprised 151 women (Adult-IVI n¿=¿86; Pregnancy-IVI n¿=¿65). The primary outcome was 68% time-at-target [95% confidence interval (CI) 64¿71%) for Pregnancy-IVI compared with 55% (95% CI 50¿60%) for Adult-IVI (P¿=¿0.0002). Critical maternal hyperglycaemia (0% vs. 2%, P¿=¿0.02) and hypoglycaemia (2% vs. 12%, P¿=¿0.02) were both lower with Pregnancy-IVI than Adult-IVI. Neonatal hypoglycaemia was less common after Pregnancy-IVI (29%) than after Adult-IVI (54%, P¿=¿0.03). A multiple logistic regression model adjusting for potential confounders gave an odds ratio for neonatal hypoglycaemia with Pregnancy-IVI of 0.27 (95% CI 0.10¿0.76, P¿=¿0.01). Conclusions: An IVI protocol designed for pregnancy effectively controlled maternal hyperglycaemia following betamethasone administration in GDM. This is the first intervention to show a reduction in betamethasone-associated neonatal hypoglycaemia, linked with optimum maternal glycaemic control.
|
Nova | |||||||||
2019 |
Marlow AL, Rowe CW, Anderson D, Wynne K, King BR, Howley P, Smart CE, 'Young children, adolescent girls and women with type 1 diabetes are more overweight and obese than reference populations, and this is associated with increased cardiovascular risk factors.', Diabetic medicine : a journal of the British Diabetic Association, 36 1487-1493 (2019) [C1]
|
Nova | |||||||||
2018 |
Panth N, Abbott KA, Dias CB, Wynne K, Garg ML, 'Differential effects of medium- and long-chain saturated fatty acids on blood lipid profile: A systematic review and meta-analysis', American Journal of Clinical Nutrition, 108 675-687 (2018) [C1] Background Medium-chain saturated fatty acids (MCFAs) may affect circulating lipids and lipoproteins differently than long-chain saturated fatty acids (LCSFAs), but the results fr... [more] Background Medium-chain saturated fatty acids (MCFAs) may affect circulating lipids and lipoproteins differently than long-chain saturated fatty acids (LCSFAs), but the results from human intervention trials have been equivocal. Objective The aim of this study was to determine whether MCFAs and LCSFAs have differential impacts on blood lipids and lipoproteins. Design Five databases were searched (EMBASE, MEDLINE, CINAHL, Cochrane, and Scopus) until April 2018, and published clinical trials investigating the differential effects of dietary MCFAs and LCSFAs on blood lipids were included. Searches were limited to the English language and to studies with adults aged >18 y. Where possible, studies were pooled for meta-analysis using RevMan 5.2. The principle summary measure was the mean difference between groups calculated using the random-effects model. Results Eleven eligible crossover and 1 parallel trial were identified with a total of 299 participants [weighted mean ± SD age: 38 ± 3 y; weighted mean ± SD body mass index (kg/m 2): 24 ± 2]. All studies were pooled for the meta-analysis. Diets enriched with MCFAs led to significantly higher high-density lipoprotein (HDL) cholesterol concentrations than diets enriched with LCSFAs (0.11 mmol/L; 95% CI: 0.07, 0.15 mmol/L) with no effect on triglyceride, low-density lipoprotein (LDL) cholesterol, and total cholesterol concentrations. Consumption of diets rich in MCFAs significantly increased apolipoprotein A-I (apoA-I) concentrations compared with diets rich in LCSFAs (0.08 g/L; 95% CI: 0.02, 0.14 g/L). There was no evidence of statistical heterogeneity for HDL cholesterol, apoA-I, and triglyceride concentrations; however, significant heterogeneity was observed for the total cholesterol (I 2 = 49%) and LDL cholesterol analysis (I 2 = 58%). Conclusion The findings of this research demonstrate a differential effect of MCFAs and LCSFAs on HDL cholesterol concentrations. Further investigations are warranted to elucidate the mechanism by which the lipid profile is altered. This trial was registered at www.crd.york.ac.uk/PROSPERO as CRD42017078277.
|
Nova | |||||||||
2017 |
Joshi T, Oldmeadow C, Attia J, Wynne K, 'The duration of intrapartum maternal hyperglycaemia predicts neonatal hypoglycaemia in women with pre-existing diabetes', Diabetic Medicine, 34 725-731 (2017) [C1] Aim: There is a high incidence of neonatal hypoglycaemia in neonates born to mothers with pre-existing diabetes. This often necessitates admission to the neonatal intensive care. ... [more] Aim: There is a high incidence of neonatal hypoglycaemia in neonates born to mothers with pre-existing diabetes. This often necessitates admission to the neonatal intensive care. Guidelines suggest maintaining intrapartum blood glucose levels (BGLs) of 4¿7 mmol/l in women with diabetes to reduce the risk of neonatal hypoglycaemia. This study assessed whether intrapartum BGLs in women with pre-gestational Type 1 and 2 diabetes were predictive of neonatal hypoglycaemia. Methods: A retrospective analysis of 261 births delivered at a tertiary hospital in Australia from 2009 to 2014. Results: There were 122 cases of neonatal hypoglycaemia (glucose = 2.6 mmol/l) in 261 births (47%). The mothers in the neonatal hypoglycaemia group spent less time with BGL in the range 4¿7 mmol/l [55 ± 37% vs. 65 ± 35%, P = 0.02; odds ratio (OR) 0.992, P = 0.03] and more time with BGL in the 7¿10 mmol/l range (31 ± 34% vs. 18 ± 27%, P = 0.003; OR 1.013, P = 0.003) compared with those without neonatal hypoglycaemia. Although statistically significant, receiver operating characteristic (ROC) curve analysis showed that time spent with maternal BGLs in the range 4¿7 mmol/l [area under the curve (AUC) = 0.58] or 7¿10 mmol (AUC = 0.60) was not strong enough to be a useful clinical predictor of neonatal hypoglycaemia. HbA1c in the second trimester of pregnancy (P = 0.02, OR 1.42) and percentage time spent in BGL range of 7¿10 mmol/l (P = 0.001, OR 1.02) were both associated with a risk of neonatal hypoglycaemia in a logistic regression model. HbA1c in the third trimester (P = 0.07, OR 1.28) approached, but did not reach, significance. Conclusions: These data support a BGL range of 4¿7 mmol/l as an intrapartum target. Glycaemic control in the second trimester is associated with neonatal hypoglycaemia. Improvement in ante- and intrapartum glycaemic control may reduce neonatal hypoglycaemia in women with pre-existing diabetes.
|
Nova | |||||||||
2017 |
Rowe CW, Haider AS, Viswanathan D, Jones M, Attia J, Wynne K, Acharya S, 'Insulin resistance correlates with maculopathy and severity of retinopathy in young adults with Type 1 Diabetes Mellitus', Diabetes Research and Clinical Practice, 131 154-160 (2017) [C1] Aims To assess the relationship between insulin resistance (IR), retinopathy and maculopathy in young adults with Type 1 diabetes mellitus. Methods A cross-sectional study at a re... [more] Aims To assess the relationship between insulin resistance (IR), retinopathy and maculopathy in young adults with Type 1 diabetes mellitus. Methods A cross-sectional study at a regional Australian tertiary hospital. Retinal pathology, assessed by colour fundus photography, was correlated with two surrogate measures of IR: estimated Glucose Disposal Rate (eGDR) and Insulin Sensitivity Score (ISS), where lower scores reflect greater IR. Results 107 patients were recruited, with mean age 24.7¿years, 53% male, and mean duration of disease 10.8¿years. Mean eGDR scores (5.6¿vs 8.0 p¿<¿0.001) and ISS (4.7¿vs 7.9, p¿<¿0.001) were lower in subjects having at least moderate non-proliferative diabetic retinopathy (NPDR; relative to nil/mild-NPDR). Similarly, mean eGDR (4.2¿vs 6.2, p¿=¿0.001) and ISS (3.8¿vs 6.1, p¿=¿0.003) were lower in patients with maculopathy. Multivariate logistic regression modelling was used to control for confounding. For retinopathy severity, a unit increase in eGDR or ISS (representing lower IR) was associated with a 50% decrease in odds of moderate-NPDR or worse (eGDR OR 0.5, 95%CI 0.32¿0.77, p¿=¿0.002; ISS OR 0.49, 95%CI 0.29¿0.84, p¿=¿0.01). A unit increase in eGDR or ISS was associated with a 46¿56% decrease in odds of maculopathy (eGDR OR 0.54, 95%CI 0.37¿0.81, p¿=¿0.003; ISS OR 0.44, 95%CI 0.22¿0.88, p¿=¿0.02). Conclusions IR correlates with more severe retinopathy in young adults with Type 1¿DM. This is the first description of a correlation between IR and maculopathy in Type 1¿DM, warranting further evaluation. Prospective studies examining whether reducing IR can improve microvascular complications are required.
|
Nova | |||||||||
2016 |
Rollo ME, Aguiar EJ, Williams RL, Wynne K, Kriss M, Callister R, Collins CE, 'Ehealth technologies to support nutrition and physical activity behaviors in diabetes self-management', Diabetes, Metabolic Syndrome and Obesity, 9 381-390 (2016) [C1] Diabetes is a chronic, complex condition requiring sound knowledge and self-management skills to optimize glycemic control and health outcomes. Dietary intake and physical activit... [more] Diabetes is a chronic, complex condition requiring sound knowledge and self-management skills to optimize glycemic control and health outcomes. Dietary intake and physical activity are key diabetes self-management (DSM) behaviors that require tailored education and support. Electronic health (eHealth) technologies have a demonstrated potential for assisting individuals with DSM behaviors. This review provides examples of technologies used to support nutrition and physical activity behaviors in the context of DSM. Technologies covered include those widely used for DSM, such as web-based programs and mobile phone and smartphone applications. In addition, examples of novel tools such as virtual and augmented reality, video games, computer vision for dietary carbohydrate monitoring, and wearable devices are provided. The challenges to, and facilitators for, the use of eHealth technologies in DSM are discussed. Strategies to support the implementation of eHealth technologies within practice and suggestions for future research to enhance nutrition and physical activity behaviors as a part of broader DSM are provided.
|
Nova | |||||||||
2013 |
Cegla J, Jones B, Seyani L, Papadoulou D, Wynne K, Martin NM, et al., 'Comparison of the overnight metyrapone and glucagon stimulation tests in the assessment of secondary hypoadrenalism', CLINICAL ENDOCRINOLOGY, 78 738-742 (2013) [C1]
|
||||||||||
Show 57 more journal articles |
Conference (18 outputs)
Year | Citation | Altmetrics | Link | |||||
---|---|---|---|---|---|---|---|---|
2023 |
Carroll O, Brown A, Mayall J, Gomez H, Kim R, Donovan C, et al., 'A relationship between female sex hormones, cellular metabolism, and asthma', RESPIROLOGY (2023)
|
|||||||
2022 |
Carroll O, Brown A, Mayall J, Zounemat-Kermani N, Gomez H, Kim R, et al., 'Female sex hormones affect asthma severity by altering cellular metabolism in the airways', EUROPEAN RESPIRATORY JOURNAL (2022)
|
|||||||
2021 |
Croker E, Mohammad N, Rowe C, Wynne K, 'Accuracy of continuous glucose monitoring during periods of predicted acute glycaemic variability in pregnancy in women with Type 1 Diabetes Mellitus in the inpatient setting: A pilot study', Virtual (2021)
|
|||||||
Show 15 more conferences |
Preprint (2 outputs)
Year | Citation | Altmetrics | Link | |||||
---|---|---|---|---|---|---|---|---|
2023 |
Alvarez S, Fellas A, Wynne K, Santos D, Sculley D, Acharya S, et al., 'The role of SmartWatch Technology in the provision of care for type 1 or type 2 Diabetes Mellitus or Gestational Diabetes: a systematic review. (Preprint) (2023)
|
|||||||
2022 |
Diez Alvarez S, Fellas A, Santos D, Sculley D, Wynne K, Acharya S, et al., 'The Clinical Impact of Flash Glucose Monitoring a Digital Health App and Smartwatch Technology in Patients With Type 2 Diabetes: Scoping Review (Preprint) (2022)
|
Grants and Funding
Summary
Number of grants | 24 |
---|---|
Total funding | $7,496,255 |
Click on a grant title below to expand the full details for that specific grant.
Highlighted grants and funding
COSMAT Study - co-designed shared model of care for gender affirming hormone therapy$1,000,000
Funding body: Medical Research Future Fund
Funding body | Medical Research Future Fund |
---|---|
Project Team | Cheung A, Nolan B, Zwickl S, Cook T, Locke P, Leemaqz S, Wynne K, Dutton M, Tran-Duy A |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2024 |
Funding Finish | 2029 |
GNo | |
Type Of Funding | C1300 - Aust Competitive - Medical Research Future Fund |
Category | 1300 |
UON | N |
20243 grants / $6,018,203
ARCTYC – Improving health outcomes via the Australian Research Consortium for Trans Youth and Children$4,999,773
Funding body: Medical Research Futures Fund (MRFF)
Funding body | Medical Research Futures Fund (MRFF) |
---|---|
Project Team | CIA Pang K, Cis Anderson J, Bista S, Bourne A, Byrne M, Canty J, Cavve B, Cheung A, Coghill D, Colon Cabrera D, Cooper M, Crock P, Cronin T, Davies, C, Donaghy O, Dutton M, Furzer B, Knight K, Lane R, Lin A, Marino J, McKercher K, Mihalopoulos C, Moor J, Morgan H, Newman C, O’Connell M, Pace C, Perry Y, Ravine A, Riggs D, Robinson K, Russel F, Saunders L, Siafarikas A, Simmons M, Skinner S, Stathis S, Strauss P, Telfer M, Titmuss A, Tollit M, Uink B, Wiggins J, Wynne K, Zbukvic I, Zwickl S |
Scheme | NHMRC MRFF Models of Care for Sexuality & Gender Diverse People & People with Innate Variations of Sex Characteristics Grant Opportunity (Stream 4) |
Role | Investigator |
Funding Start | 2024 |
Funding Finish | 2028 |
GNo | |
Type Of Funding | C1100 - Aust Competitive - NHMRC |
Category | 1100 |
UON | N |
COSMAT Study - co-designed shared model of care for gender affirming hormone therapy$1,000,000
Funding body: Medical Research Future Fund
Funding body | Medical Research Future Fund |
---|---|
Project Team | Cheung A, Nolan B, Zwickl S, Cook T, Locke P, Leemaqz S, Wynne K, Dutton M, Tran-Duy A |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2024 |
Funding Finish | 2029 |
GNo | |
Type Of Funding | C1300 - Aust Competitive - Medical Research Future Fund |
Category | 1300 |
UON | N |
Investigating the effect of feminizing, gender-affirming hormone therapies on respiratory outcomes. $18,430
Funding body: John Hunter Charitable Trust
Funding body | John Hunter Charitable Trust |
---|---|
Project Team | Brown AC, Carroll OR, Wynne K, Horvat JC |
Scheme | John Hunter Charitable Trust Grant |
Role | Investigator |
Funding Start | 2024 |
Funding Finish | 2025 |
GNo | |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | N |
20233 grants / $186,700
HNELHD transgender health clinic 25+years: capacity-building, service redesign and evaluation$165,000
Funding body: NSW ministry of health
Funding body | NSW ministry of health |
---|---|
Project Team | K Wynne, J Mesure, J Luu, A Turrell, B Britton, T Cook, D McCarthy, K Gold, K Hildred, M McKenzie, S Fitzgerald, A Boyes, R Wyse. |
Scheme | NSW LGBTIQ+ Health Funding Pool 2023-2024 and 2024-25 |
Role | Lead |
Funding Start | 2023 |
Funding Finish | 2025 |
GNo | |
Type Of Funding | C1600 - Aust Competitive - StateTerritory Govt |
Category | 1600 |
UON | N |
Enhancing medication adherence, physical activity, and mental health amongst LGBTIQ+ young adults through an innovative digital health intervention: a feasibility, acceptability, and pilot randomized control trial$20,700
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Coda A, Wynne K, Gilligan C and James D |
Scheme | HMRI Equity in Health and Wellbeing Research Program Seed Grant Scheme |
Role | Investigator |
Funding Start | 2023 |
Funding Finish | 2024 |
GNo | |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | N |
LGBTQI+-inclusive Health Professions Education: producing meaningful change in the healthcare learning environment through faculty development.$1,000
Funding body: NSW Regional Health Partners
Funding body | NSW Regional Health Partners |
---|---|
Project Team | Leopardi E, Unicomb R, McGee R, Horton G, Wynne K |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2023 |
Funding Finish | 2024 |
GNo | |
Type Of Funding | C1600 - Aust Competitive - StateTerritory Govt |
Category | 1600 |
UON | N |
20222 grants / $422,484
HMRI Research Program award for program 'Equity in Health & Wellbeing’ - Complex and Chronic Disease group$412,000
Funding body: Hunter Medical Research Institute (HMRI)
Funding body | Hunter Medical Research Institute (HMRI) |
---|---|
Project Team | Complex and Chronic Disease Group |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2022 |
Funding Finish | 2022 |
GNo | |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | N |
Effective screening for malnutrition in advanced liver disease: a patient-driven, value-based approach to medical nutrition therapy$10,484
Funding body: John Hunter Charitable Trust
Funding body | John Hunter Charitable Trust |
---|---|
Project Team | Wynne K, Attia J, Barnes P, Diekmann MA, Young J, Kerr J, Ludlow S, Pullen S |
Scheme | John Hunter Charitable Trust Grant |
Role | Lead |
Funding Start | 2022 |
Funding Finish | 2022 |
GNo | |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | N |
20211 grants / $18,182
Controlling high glucose levels after antenatal steroids in women with diabetes in pregnancy$18,182
Funding body: John Hunter Charitable Trust
Funding body | John Hunter Charitable Trust |
---|---|
Project Team | Rowe C, Mohammad N, Croker E and Wynne K |
Scheme | John Hunter Charitable Trust Grant |
Role | Investigator |
Funding Start | 2021 |
Funding Finish | 2022 |
GNo | |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | N |
20203 grants / $41,162
The effect of obesity, hormones and hormone manipulation on metabolism in immune cells. $25,000
Funding body: Hunter Medical Research Institute (HMRI)
Funding body | Hunter Medical Research Institute (HMRI) |
---|---|
Project Team | Wood L, Horvat J, Wynne K, Karihaloo C, Wark P, Hsu A, Brown A, Mayall J, Jobling P, Berthon B. |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2020 |
Funding Finish | 2022 |
GNo | |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | N |
Artificial intelligence (with machine learning) to quantify nerve density in cancer with prognostic and therapeutic potential. $12,162
Funding body: John Hunter Charitable Trust
Funding body | John Hunter Charitable Trust |
---|---|
Project Team | Rowe C, Wynne K, Welsh J, Viian R and Joblin P |
Scheme | John Hunter Charitable Trust Grant |
Role | Investigator |
Funding Start | 2020 |
Funding Finish | 2022 |
GNo | |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | N |
Transform Newy’$4,000
Funding body: Newcastle City Council
Funding body | Newcastle City Council |
---|---|
Project Team | Wynne K and Hunter Gender Alliance |
Scheme | Newcastle City Council Placemaking Grants 2020 |
Role | Investigator |
Funding Start | 2020 |
Funding Finish | 2021 |
GNo | |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | N |
20192 grants / $21,013
Islet Amyloid Polypeptide (IAPP) as a novel biomarker for cystic fibrosis-related diabetes$20,063
Funding body: John Hunter Hospital Charitable Trust
Funding body | John Hunter Hospital Charitable Trust |
---|---|
Project Team | Doctor Katie Wynne, Prof MANOHAR Garg, Mr Rohith Thota |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2019 |
GNo | G1900257 |
Type Of Funding | C2400 – Aust StateTerritoryLocal – Other |
Category | 2400 |
UON | Y |
Legal Rights, Protections and Barriers for the Trans and Gender Diverse Community across the Lifespan$950
Funding body: ACON Health
Funding body | ACON Health |
---|---|
Project Team | Wynne K on behalf of the Hunter Gender Alliance |
Scheme | IDAHOBIT Grant |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2019 |
GNo | |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | N |
20182 grants / $34,409
Improving Timely Access to Evidence-based Transgender Health Services: A Novel Web-based Approach$27,809
Funding body: Hunter New England Area Health Service
Funding body | Hunter New England Area Health Service |
---|---|
Project Team | Nunn L, Lopez P, Crock P and Wynne K |
Scheme | Innovation Scholarship |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2019 |
GNo | |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | N |
Funding for a Hunter Region Conference for people that identify as Trans and Gender Diverse their allies and health professionals$6,600
Funding body: The Aurora Project
Funding body | The Aurora Project |
---|---|
Project Team | Mills J, Kelly S, Kelly J and Wynne K on behalf of the Hunter Gender Alliance |
Scheme | Aurora Project Grant |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2019 |
GNo | |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | N |
20174 grants / $166,594
Long chain omega-3 polyunsaturated fatty acids for the prevention of gestational diabetes: A double-blind randomized controlled trial $60,255
Funding body: BASF (Asia Pacific)
Funding body | BASF (Asia Pacific) |
---|---|
Project Team | Prof MANOHAR Garg, Mrs Kylie Abbott, Doctor Sham Acharya, Professor Tracy Burrows, Doctor Katie Wynne, Dr Wendy Carseldine |
Scheme | Newtrition Asia Research Grant |
Role | Investigator |
Funding Start | 2017 |
Funding Finish | 2018 |
GNo | G1601197 |
Type Of Funding | C3400 – International For Profit |
Category | 3400 |
UON | Y |
Evaluation of a type 2 diabetes risk reduction program for women with recent gestational diabetes$59,911
Funding body: Diabetes Australia
Funding body | Diabetes Australia |
---|---|
Project Team | Rollo M, Collins C, Callister R, Hutchesson M, Aguiar E, Wynne K and Young A |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2017 |
Funding Finish | 2019 |
GNo | |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | N |
Active pregnancy intervention for women with first trimester hyperglycaemia$24,575
Funding body: John Hunter Charitable Trust
Funding body | John Hunter Charitable Trust |
---|---|
Project Team | Ewald B, Wynne K |
Scheme | Charitable trust grant |
Role | Investigator |
Funding Start | 2017 |
Funding Finish | 2018 |
GNo | |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | N |
Demand, acceptability and preliminary efficacy of a type 2 diabetes risk reduction program for women with recent gestational diabetes$21,853
Funding body: Hunter Medical Research Institute (HMRI)
Funding body | Hunter Medical Research Institute (HMRI) |
---|---|
Project Team | Collins C, Callister R, Rollo M, Hutchesson M, Aguiar E, Wynne K and Young A |
Scheme | Diabetes Research Grant |
Role | Investigator |
Funding Start | 2017 |
Funding Finish | 2019 |
GNo | |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | N |
20161 grants / $23,848
Sweetdreams: Targeting obesity to improve Obstructive Sleep Apnoea and Health Outcomes in Type 2 Diabetes$23,848
Funding body: Hunter New England Area Health Service
Funding body | Hunter New England Area Health Service |
---|---|
Project Team | Pullen S, Baines S, Pradeepan S, Osmotherly P and Wynne K |
Scheme | Innovation Scholarship |
Role | Lead |
Funding Start | 2016 |
Funding Finish | 2018 |
GNo | |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | N |
20151 grants / $28,660
A randomized double-blind placebo-controlled trial of high-dose pre-operative cholecalciferol to prevent post-thyroidectomy hypocalcaemia$28,660
Funding body: John Hunter Charitable Trust
Funding body | John Hunter Charitable Trust |
---|---|
Project Team | Arthurs S, Carroll R, Wynne K and Bendinelli C |
Scheme | Charitable trust grant |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2016 |
GNo | |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | N |
20071 grants / $279,000
Appetite Control$279,000
Funding body: Higher Education Funding Council for England
Funding body | Higher Education Funding Council for England |
---|---|
Project Team | Wynne K and Bloom SR |
Scheme | Higher Level Skills Partnership |
Role | Lead |
Funding Start | 2007 |
Funding Finish | 2010 |
GNo | |
Type Of Funding | International - Competitive |
Category | 3IFA |
UON | N |
20031 grants / $256,000
Is the loss of appetite sustained weight reduction after gastric bypass surgery due to changes in two gut hormones?$256,000
Funding body: Wellcome Trust
Funding body | Wellcome Trust |
---|---|
Project Team | Wynne K and Bloom SR |
Scheme | Research Training Fellowship |
Role | Lead |
Funding Start | 2003 |
Funding Finish | 2007 |
GNo | |
Type Of Funding | International - Competitive |
Category | 3IFA |
UON | N |
Research Supervision
Number of supervisions
Current Supervision
Commenced | Level of Study | Research Title | Program | Supervisor Type |
---|---|---|---|---|
2022 | PhD | The Influence of the Assessor when Providing Narrative Feedback on Assessments to Undergraduate Medical Students and the Impact of This Feedback on Professional Identity in Medicine | PhD (Medical Education), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2021 | Masters | Validation of Continuous Glucose Monitoring During Periods of Acute Glycaemic Variability in Pregnancy (After Betamethasone or During Labour) | M Philosophy (Medicine), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2020 | PhD | Type 1 Diabetes in Pregnancy – Nutrition Intake, Self, Management Skills and Food Relationships | PhD (Medicine), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2016 | PhD | Metabolically Healthy Obesity and Its Association with Adverse Health Outcomes | PhD (CommunityMed & ClinEpid), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
Past Supervision
Year | Level of Study | Research Title | Program | Supervisor Type |
---|---|---|---|---|
2024 | PhD | Risk Factors for Overweight and Obesity in Children and Adolescents with Type 1 Diabetes | PhD (Medicine), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2019 | Masters | Differential Effects of Saturated Fatty Acids of Varying Chain Length on Lipid Profiles in Healthy Individuals | M Philosophy (Nutritl Biochem), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
Dr Katie Wynne
Position
Conjoint Associate Professor
School of Medicine and Public Health
College of Health, Medicine and Wellbeing
Contact Details
katie-jane.wynne@newcastle.edu.au | |
Phone | 02 4921 4380 |
Office
Location | John Hunter Hospital , |
---|